GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » Debt-to-Asset

Q32 Bio (Q32 Bio) Debt-to-Asset : 0.13 (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Q32 Bio Debt-to-Asset?

Q32 Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $4.65 Mil. Q32 Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $15.50 Mil. Q32 Bio's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $152.33 Mil. Q32 Bio's debt to asset for the quarter that ended in Mar. 2024 was 0.13.

Q32 Bio Debt-to-Asset Historical Data

The historical data trend for Q32 Bio's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q32 Bio Debt-to-Asset Chart

Q32 Bio Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-Asset
0.14 0.72 1.08

Q32 Bio Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial 0.72 - 0.93 1.08 0.13

Competitive Comparison of Q32 Bio's Debt-to-Asset

For the Biotechnology subindustry, Q32 Bio's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Q32 Bio's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q32 Bio's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Q32 Bio's Debt-to-Asset falls into.


Q32 Bio Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Q32 Bio's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1.416 + 49.424) / 47.057
=1.08

Q32 Bio's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(4.648 + 15.499) / 152.334
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q32 Bio  (NAS:QTTB) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Q32 Bio Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Q32 Bio's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Q32 Bio (Q32 Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » Debt-to-Asset
Comparable Companies
Traded in Other Exchanges
N/A
Address
830 Winter Street, Waltham, MA, USA, 02451
Website
https://www.q32bio.com
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Q32 Bio (Q32 Bio) Headlines

From GuruFocus

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

By PRNewswire • 04-03-2024